Stereotactic Radiosurgery for Multiple Brain Metastases From Renal-Cell Carcinoma.

Clin Genitourin Cancer 2019 04 22;17(2):e273-e280. Epub 2018 Nov 22.

Kidney Cancer Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX; Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX.

Background: Brain metastases (BM) pose a significant problem in patients with metastatic renal-cell carcinoma (mRCC). Local and systemic therapies including stereotactic radiosurgery (SRS) are rapidly evolving, necessitating reassessments of outcomes for modern patient management.

Patients And Methods: The mRCC patients with BM treated with SRS were reviewed. Patient demographics, clinical history, and SRS treatment parameters were identified.

Results: Among 268 patients with mRCC treated between 2006 and 2015, 38 patients were identified with BM. A total of 243 BM were treated with SRS with 1 to 26 BMs treated per SRS session (median, 2 BMs). The median (range) BM size was 0.6 (0.2-3.1) cm and median (range) SRS treatment dose was 18 (12-24) Gy. Treated BM local control rates at 1 and 2 years were 91.8% (95% confidence interval, 85.7-95.4) and 86.1% (95% confidence interval, 77.1-91.7), respectively. BM control declined for larger tumors. Survival after 1-year was 57.5% (95% CI 40.2-71.4) for all patients. Survival was not statistically different between patients with < 5 BM versus ≥ 5 BM. Survival was prognostic based on International Metastatic Renal Cell Carcinoma Database (IMDC) risk groups in patients with < 5 BM. Two patients experienced grade 3 radiation necrosis requiring surgical intervention.

Conclusion: SRS is effective in controlling BM in patients with mRCC. Over half of treated patients survive past a year, and no differences in survival were noted in patients with > 5 metastases. Prognostic risk categories based on systemic disease (IMDC) are predictive of survival in this BM population, with limited rates of symptomatic radiation necrosis.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.11.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563340PMC
April 2019
16 Reads
1.693 Impact Factor

Publication Analysis

Top Keywords

treated srs
12
patients
11
confidence interval
8
srs treatment
8
renal-cell carcinoma
8
95% confidence
8
median range
8
radiation necrosis
8
brain metastases
8
patients mrcc
8
stereotactic radiosurgery
8
patients with <
8
srs
7
treated
6
survival
5
with < patients
4
bms median
4
median bms
4
risk groups
4
range srs
4

Similar Publications